PMID: 9849822
Peptide Research
Ipamorelin
SKU: KRS-IPA-10
Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively agonizes the ghrelin receptor (GHS-R1a) on pituitary somatotrophs. Developed by Novo Nordisk from the GHRP-1 scaffold, it was the first GHRP-receptor agonist with GH-release selectivity comparable to GH…
View Catalog →For Research Use Only
Mechanism of Action
Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively agonizes the ghrelin receptor (GHS-R1a) on pituitary somatotrophs. Developed by Novo Nordisk from the GHRP-1 scaffold, it was the first GHRP-receptor agonist with GH-release selectivity comparable to GHRH. Unlike GHRP-6 or GHRP-2, it produces GH release without meaningful stimulation of ACTH, cortisol, prolactin, FSH, LH, or TSH, even at doses >200x the ED50 for GH release.
Research Studies
1 peer-reviewed study curated for Ipamorelin.
Other — 1
Related Research
Frequently combined with CJC-1295 for synergistic GH release research. Compared with Tesamorelin for different mechanism of GH-axis activation. Paired with IGF-1 LR3 for downstream anabolic studies.